Evaluation In- Network & Out-of-Network Pharmacy Trends

In part two of our drug trends series, we look at trends from our combined prospectively and retrospectively managed network channels to address the total view of prescription activity.

Infographic Summary

In part two of our series, we’re seeing overall utilization trending downward; however, cost of scripts is on the rise, driven by high-dollar topical agents that come almost-exclusively from out-of-network channels, as well as increased utilization and spend within the migraine category, and rising trends in average wholesale price for certain drug products, especially brand medications.

To view future installments of the drug trends series, be sure to visit our drug trends page.

Register to download the full content


To learn more from Enlyte, please visit their website.

Enlyte is the parent brand of Mitchell | Genex | Coventry, a leader in cost-containment technology, independent medical exams (IME), provider and specialty networks, case management services, pharmacy benefit and disability management. The three businesses have recently aligned their joint industry expertise and advanced technology solutions into a combined organization of nearly 6,000 associates committed to simplifying and optimizing property, casualty and disability claims processes and services.

More from Risk & Insurance